Replies to post #2731 on Enanta Pharmaceuticals Inc (ENTA)

[alertmeipp]

I think RBCs point is with vaccine, less harmful covid variant and natural immunity, hospitalization rate is lower than before, thus it’s harder than before to show stats significance on the same endpoint. (Reduce hospitalization rate)


So for 235, the regulatory pathway isn’t clear for them.

That’s probably one of the reason 235 get discounted by the market even it seems to be superior drug

Hope ENTA can work out the details with FDA and update the market soon